According to SNS Insider, the global RNAi Technology Market was valued at USD 3.02 billion in 2024 and is projected to reach USD 9.03 billion by 2032, expanding at a CAGR of 14.68% over 2025–2032. RNA ...

Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company’s ...

-- Novel approach to gene knockdown uses proprietary CASi (Conditionally Activated siRNA) molecules optimized to “switch” on, activating siRNA therapeutics only in selected cells -- -- CASi platform, ...

It was not until 2018 that the US FDA approved the first therapy developed using the technique. Since then, there’s been a steady, but slow, number of RNAi treatments coming into the market. The ROBO ...

An update from Veritas In Silico Inc. ( ($JP:130A) ) is now available. Veritas In Silico Inc. and Dexerials Corporation have announced a joint ...

Learn how advanced molecular dynamics simulations can improve RNA-based therapeutics by modeling complex folding processes.

This webinar will highlight how circular RNA overcomes key challenges in in vivo CAR-T therapy, with case examples from YXgene’s circRNA platform. In vivo CAR-T therapy is emerging as a transformative ...

The MarketWatch News Department was not involved in the creation of this content. AUSTIN, Texas and TOKYO, Sept. 4, 2025 /PRNewswire/ -- According to DataM Intelligence, the RNAi technology market ...

LONDON--(BUSINESS WIRE)--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference ...